组蛋白去乙酰化酶抑制剂在外周T细胞淋巴瘤中的应用进展

外周T细胞淋巴瘤（peripheralTcelllymphoma，PTCL）是一类具有高度异质性的起源于成熟T细胞或NK细胞的恶性肿瘤，大多数类型侵袭性高、进展快，总体预后不佳。表观遗传修饰对PTCL在内的恶性肿瘤的发生发展起重要作用。目前与表观遗传调控相关的组蛋白去乙酰化酶抑制剂（histonedeacetylaseinhibitors，HDACi）已经用于PTCL的治疗，在单药及联合治疗时显示出良好的耐受性和治疗效果，其中伏立诺他、罗米地辛、贝利司他和西达本胺已先后被批准上市。本文对HDACi在PTCL治疗方面的应用进展进行综述。 

Advances in histone deacetylase inhibitors for the treatment of peripheral T-cell lymphoma

Peripheral T-cell lymphoma (PTCL) is a group of highly heterogeneous non-Hodgkin's lymphomas derived from mature T or NK cells. Most subtypes of PTCL are highly aggressive with rapid growth and poor prognosis. Recently, epigenetic modification has been reported to play an important role in the evolution and progression of cancers, especially PTCL. Therefore, as a novel antineoplastic agent, histone deacetylase inhibitor has already been used in treating PTCL. The histone deacetylase inhibitor with or without chemotherapy or other therapies showed good tolerance and significant efficacy. Several histone deacetylase inhibitors, such as vorinostat, romidepsin, belinostat, and chidamide, have been approved by the FDA or CFDA. This review summarizes the advances of using histone deacetylase inhibitors as an alternative anti-cancer therapeutic strategy for the treatment of PTCL.